73 results about "Residual Tumors" patented technology

A radiotherapeutic apparatus using high-energy electron beams to radiate the bed of removed tumor and the residual tumor tissue in excision operation features that the CT or MRI 3D imaging software is used to determine the position of tumor focal, an analog technique is used to determine the incident direction, angle and position of electron beam, a radiotherapeutic plan system is used to calculate the radiation dosage, and a laser locator on the radiating head with straight-line electron accelerator is used to align the electron beam to the tumor focal.

The present invention relates to a diagnostic unit for diagnosing early cancel depending on fluorescent image. The invention adopts a real time display method for fluorescent image, which has high spatial-resolution and high time-resolution for the purpose of collecting information about all fluorescent images of diagnostic area at any time without omission of any detail. Method of the present invention is prior to method catching static images in diagnosis, and the invention prevents mistakes and missed check caused by failure in acquiring static images timely and accurately in order to improve accuracy rate during the test of early cancer. The present invention has the advantages of accurate, direct, convenient and easy operation with no side effects, which can be used in diagnosing all malignant tumors inside and outside human body. Before operation, the present invention can favor fixing range of the operation. When in operation, the invention can conduct tracking and check so as to adjust effect of the operation and suggest for removing residual tumor in time.

This invention provides medicaments and methods for managing cancer using donor cells that are alloactivated in culture. Alloactivated cells are implanted into the bed of a solid tumor and initiate a response by the host against the tumor. Subsequently, alloactivated cells are implanted into the bed of a solid tumor a second time. The two implants work synergistically to confer remarkable benefit to the treated subject, both in terms of management of the cancer and the development of an anti-cancer immune response. The beneficial effects may include regression of the tumor and extended survival. Removal of any residual tumor after the second implant facilitates ongoing resistance to tumor regrowth or metastasis.

Apparatus and methods are presented herein that permit real-time, accurate detection of residual tumor in the operating room. The Raman-based wide-field imaging apparatus and methods described herein permit real-time imaging of tumor-targeted R-MR nanoparticles over a wide field.

A sustained-release gel injection comprises sustained-release microspheres containing taxanes drug, amphiphilic block copolymer, solvent and release regulator, wherein the mixture of the amphiphilic block copolymer and the solvent has a temperature sensitive gelatinization characteristic, and can automatically become non-flowing degradable water insoluble gel, which can locally and slowly release drug at tumor foci for several weeks to several months, after injection into body. The preparation can be injected into or around a tumor for treating solid tumors at different stages. The preparation has the effects of controlling residual tumor cells relapsed after operation and tumors that can not be excised via operation, controlling complications at late stage of tumors, and enhancing treatment effect of chemotherapy and radiotherapy (particularly radioactive particles). The taxanes are selected from docetaxel, taxol, epitaxol, hydroxyl taxol and deacetyltaxol; the amphiphilic block copolymer is PLGA-PEG-PLGA copolymer, wherein the PEG has molecular weight of 1200-1600, accounting for 20 wt% of the amphiphilic block copolymer; and in the glycolide-lactide copolymer, the mol ratio of glycolide and lactide is 6:1.

The invention relates to a graphene-modified biological ceramic support material and a preparing method and application thereof. The graphene-modified biological ceramic support material comprises a beta-tricalcium phosphate support and a graphene layer with which the surface of the beta-tricalcium phosphate support is evenly covered. The graphene-modified biological ceramic support material has the quite good anti-tumor capacity and the osteogenesis promoting characteristic, and can serve as a repairing material for excising bone tumor; meanwhile, the photo-thermal performance of the graphene-modified biological ceramic support material is used, residual tumor cells are killed, and the dual effects of treating and repairing are achieved.

The invention provides a CAR-T cell capable of efficiently and stably expressing an inhibiting antibody and application thereof. Specifically, the invention provides a transgenic T cell, and the genome of the transgenic T cell is stably integrated with expression cassettes containing nucleic acid sequences coding chimeric antigen receptors and immune checkpoint inhibiting antibodies, wherein two ends of the expression cassettes contain inverted terminal repeats of transposons. In the genome of the pluripotent CAR-T cell, the expression cassettes of the inhibiting antibodies are stably integrated via a transposon system, so the CAR-T cell has the activity of stably and efficiently expressing the inhibiting antibodies on the premise that original killing activity of the T cell is maintained, transfer-back CAR-T cells are prevented from inhibition by a tumor microenvironment, and residual tumor-specific T cells can be activated in situ. Meanwhile, a molecular brake system is introduced to ensure the security of CAR-T cell therapy, and transfer-back pluripotent CAR-T cells can be timely removed if necessary.

The invention relates to antibody coupling bismuth selenide nanometer particles for united treatment of tumor thermal treatment and immunotherapy and a preparation method of the antibody coupling bismuth selenide nanometer particles, and belongs to the field of a pharmaceutical preparation. According to the antibody coupling bismuth selenide nanometer particles, amination bismuth selenide is usedas a carrier, PEG is used as a cross-linking agent, and a CD47 resisting antibody is coupled to the surfaces of the nanometer particles. After an antibody coupling bismuth selenide nanometer particlesuspension is intravenously injected, the nanometer particles can be massively gathered to a tumor part in a targetted manner through an EPR effect, and the condition that drug administration of the CD47 resisting antibody to whole bodies of causes anemia, is avoided. Besides, the surface-modified CD47 resisting antibody and tumor cell surfaces are high-expressed CD47 molecule specific recognition, and CD47 and SIRP alpha signal channels are closed, so that macrophages anew obtain the capacity for swallowing tumor cells. Particularly, tumor cells are subjected to thermal treatment, the residual tumor cells are eliminated by the macrophages because a signal channel free from drug administration is closed, and the purpose of thoroughly eradicating rumors is realized. The method is reasonablein design, and simple in preparation technology, has broad application prospects, and lays a foundation for design and development of a corresponding drug administration system.

The invention discloses a preparation and application method for injectable temperature-sensitive magnetic supramolecular gel. The preparation method comprises the following steps that 1, alpha-cyclodextrin and a water-soluble antineoplastic drug are added into ultrapure water, vortex mixing is carried out, and ultrasonic heating is carried out to enable the alpha-cyclodextrin and the water-soluble antineoplastic drug to be completely dissolved so as to form a solution I; 2, aqueous phase transfer is carried out on oil-soluble ferroferric oxide nano-particles prepared by a high-temperature thermal decomposition method by using 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methox (polyethylene glycol)-2000] (DSPE-mPEG2000), and meanwhile, a fat-soluble antineoplastic drug is loaded soas to obtain a solution II; and 3, the solution I and the solution II are mixed and are uniformly stirred, and standing is carried out at room temperature so as to obtain the magnetic supramolecular gel. The gel has the shear-thinning-injectable and phase-transition-temperature-adjustable properties, and the hierarchical structure of the gel can be loaded with hydrophilic and hydrophobic diphasicantineoplastic drugs; and residual tumors can be eliminated by the gel from the three aspects of uniform and staged drug release in tumor regions for a long time and cell thermal therapy and heat-promoted local high-concentration drug release caused by heat mediated by the magnetic nano-particles in the phase change conformal process.

The invention provides a preparation method of a targeted temperature-controlled water-loading silibinin temperature-sensitive lipidosome-microbubble complex drug delivery system. The preparation method comprises the following steps of with single-palmitoyl phosphatidyl choline, dipalmitoyl phosphatidyl choline, distearoyl phosphatidyl ethanolamine-polyethylene glycol-amino and silibinin as raw materials, preparing water-loading silibinin temperature-sensitive lipidosome by virtue of a membrane rotary evaporation method; and coupling the water-loading silibinin temperature-sensitive lipidosome with an ultrasonic contrast agent, namely SonoVue microbubble, so as to prepare the targeted temperature-controlled water-loading silibinin temperature-sensitive lipidosome-microbubble complex drug delivery system. According to the preparation method, a new drug delivery system is established by combining the temperature-sensitive lipidosome with the microbubble; the efficient release of local tissues of a drug at a sub-high temperature field are achieved by virtue of the targeted explosion of the microbubble and the local temperature control effect of the temperature-sensitive lipidosome, so that the bioavailability of the drug is improved, and furthermore, residual tumors during thermal ablation treatment are reduced.

The invention relates to an anticancer sustained release gel injection with stine drugs, comprising sustained release microspheres with stine drugs, a amphiphilic block copolymer, solvent and releasing moderator; wherein, the mixture of the amphiphilic block copolymer and the solvent possesses sensitive gelation property; after in vivo injection, the injection can be transformed into nonflowing, biodegradable gel insoluble in water; the insoluble gel can release the contained drugs in local tumor for weeks, even months. Intra-tumor injection or local injection can be used to treat different tumors and unresectable tumors, control late complications and the postoperative residual tumor cell recurrent, reinforce the effect of radiotherapy and chemotherapy and the effect of radiotherapy particles; nimustine and carmustine and other stines; the amphiphilic block copolymer is a PLGA-PEG-PLGA copolymer with the molecular weight of PEG 1200-1600 accounting for 20% of the amphiphilic block copolymer weight; in the poly lactide coglycolide copolymer, the molar ratio of glycolide and lactide is 6:1.

An intratumoral modulation therapy (IMT) method for the treatment of nervous system and systemic tumor in a patient which includes: (a) chronically implanting an electrode adjacent to or in the tumor of the patient or in a residual tumor bed, the electrode having electrical leads connected thereto; and (b) generating electric stimulation and applying the electric stimulation through the electrical leads to the electrode adjacent to or within the tumor. A method of transferring genetic material to a tumor cell which includes: (a) positioning an electrode adjacent to the tumor cell, the electrode having electrical leads connected thereto; (b) generating electric stimulation and applying the electric stimulation through the electrical leads to the electrode adjacent the cancer cell; and (c) delivering the genetic material to the tumor cell treated with the continuous alternating electric stimulation.

The invention also discloses an immune isolated cell medicine, its preparing process and its application in killing tumors, wherein the product comprises semipermeable-immunological isolation film bundled active cells of the cutting immunological reactive substance, the reactive cells can excrete factors for suppressing tumor growth and / or eradicate tumor cells, its using process comprises injecting the medicament into tumor tissues or residual tumor tissues after surgery resection so as to eradicate tumor cells and / or suppress tumor tissue growth.

The invention provides composite mesoporous bioglass / graphene oxide bone cement and a preparation method thereof. The composite mesoporous bioglass / graphene oxide bone cement is used for bone defect repair and residual tumor therapy after bone tumor operations and is provided with a photothermal effect. The preparation method of the composite mesoporous bioglass / graphene oxide bone cement includes: (1) preparing graphene oxide; (2) preparing mesoporous bioglass powder; (3) preparing bone cement curing liquid; (4) preparing the composite mesoporous bioglass / graphene oxide bone cement with the photothermal effect. The prepared bone cement has higher mechanical strength as compared with a pure mesoporous bioglass bone cement, is high in biocompatibility and biological activity and capable offacilitating proliferation, differentiation and osteogenesis of bone marrow mesenchymal stem cells, and is expected to provide a new strategy for bone defect reparative therapy after the bone tumor operations clinically.

The disclosure relates to systems, software, and methods for the detection of residual disease, e.g., residual tumor disease, in subjects, e.g., human cancer patients.

The invention discloses an iodipin and targeted drug compound. The iodipin and targeted drug compound comprises iodipin and a targeted drug, and the targeted drug is targetingly gathered on an in-vivotumor area through the iodipin. The iodipin is adopted as an embolization agent or an area targeting agent, the targeted drug is taken into the tumor area, the targeted drug is targetingly gathered on the tumor area rather than acts on other non-tumor organ tissue, and therefore the side effects of the targeted drug are relieved. Some targeted drugs with an angiogenesis restraining function can restrain angiogenesis caused by inflammatory factor releasing caused by iodipin embolism, and therefore hyperplasia of residual tumor tissue causd by iodipin embolism embolism is restrained.

The invention discloses a preparation method and an application method of an individualized compensation film, which belong to the field of medical auxiliary instruments. The problem that an existingcompensation film is poor in attachment to a body surface curved surface is solved. The method comprises the steps of firstly, fixing a patient's body position capable of being repeatedly operated; then marking an identification ring completely containing a target area; then taking body surface contour data in the acquired identification ring as compensation film bottom surface data; determining contour data of the upper surface of the compensation film according to a ray effective dose range, a patient target area depth range and protected tissue depth; and generating 3D data of the compensation film through 3D modeling. The thickness non-uniform compensation film prepared by the method can further guarantee that important organs and normal tissues are protected from being damaged as muchas possible while residual tumor tissues of the patient are effectively killed. The postoperative recovery time of the patient is shortened.

The invention relates to a multi-functional stealth nanoparticle co-loaded with VP and AQ4N and modified by cRGDfK polypeptide and application thereof. The stealth nanoparticle is composed of oxidizedgraphene, cRGDfK polypeptide, photosensitizer verteporfin and anoxic activated prodrug AQ4N. According to the multi-functional stealth nanoparticle co-loaded with the VP and the AQ4N and modified bythe cRGDfK polypeptide and the application thereof, the anoxic state of tumor tissue induced by tumor vascular targeted photodynamic therapy is utilized to delivery the anoxic activated prodrug together, and the anaerobic environment is utilized to further kill residual tumor cells. The multi-functional stealth nanoparticle co-loaded with the VP and the AQ4N and modified by the cRGDfK polypeptideand the application thereof have the advantages that the drug loading capacity of a cRGDfK-pGO-VP-AQ4N nanoparticle is high, the targeting ability is strong, and the killing and anti-tumor effects ontumor cells are significantly enhanced.

The invention provides oligodeoxyribonudeotide for preventing tumor recurrence and inhibiting tumor growth as well as an application thereof. The oligodeoxyribonudeotide is in a double-strand structure and comprises a positive-sense strand and an antisense strand. The positive-sense strand has the sequence of 5'-CUGUGCGUGUGACAGCGGCUGA-3', the antisense strand has the sequence of 5'-GACACGCACACUCGCCGACU-3' or 5'-AGCCGCUGUCACACGCACAGUU-3', and the sequence can be chemically modified. The invention also provides a medicine composition containing the sequence and an application of the sequence to the preparation of medicines for preventing tumor recurrence caused by residual tumor cells after tumor extirpation or concurrent chemoradiotherapy and adult tumor growth.

The invention provides a crosslinked hemostatic sponge with hemostatic and postoperative anti-tumor functions. The cross-linked hemostatic sponge is composed of a composite three-dimensional network structure formed by cross-linked modified hyaluronic acid and collagen substances and controlled-release drug-loaded nanoparticles distributed in the composite three-dimensional network structure, and the cross-linked hemostatic sponge has a porous structure. The cross-linked modified hyaluronic acid is formed by self-crosslinking of modified hyaluronic acid, the controlled-release drug-loaded nanoparticles are combined with the cross-linked modified hyaluronic acid through chemical bonds, and the drug loaded by the controlled-release drug-loaded nanoparticles is an anti-tumor drug. The cross-linked hemostatic sponge provided by the invention not only can reduce bleeding and reduce the number of circulating tumor cells, but also can slowly release and release anti-tumor drugs into residual tumor cells and scattered tumor cells through the cross-linked and loaded drug co-delivery nanoparticles, continuously kills cancer cells, and effectively inhibits recurrence and metastasis of postoperative tumors.

A photodynamic therapy device with the function of the fluorescence diagnosis comprises a host and an operating head which is connected with the host. The interior of the host comprises a core control module which controls the operating head. The interior of the operating head aggregates LED array treatment light source, LED array fluorescence excitation light source and an image acquisition module. The host is set into the treatment mode or the diagnosis mode through controlling the open and close of the LED array fluorescence excitation light source and the LED array treatment light source. The host analyzes a fluorescence image which is collected by the image collecting module and issues a cue signal or a control command after the comparison of the analytic data and the presetting data. The photodynamic therapy device has the diagnosis module and the treatment module which can realize the site confirmation of the light scope before the treatment and the individual design of the light dose, the real-time detection of the response in the treatment and the automatic adjustment, the follow-up assessment of the lethal effect and early detection of the residual tumor after the treatment. The photodynamic therapy device also provides an operation method of the photodynamic device with the function of the fluorescent diagnosis.

The invention discloses a medicine carrying injectable implanted in-situ hydrogel which is characterized by being formed at an injection part in situ on the basis of a Schiff base reaction in a chemical bond cross-linking mode, and the hydrogel has self adaptability to the shape of an injection cavity, and is long in retention time in the cavity, and medicines are in controlled release. The hydrogel is used for filling of cavities after a tumor operation, the cavities can be rapidly filled through flowability of the in-situ hydrogel, the hydrogel can be in close contact with edge tissue aftertumor excision, residual tumor cells can be well eliminated, and a remarkable effect of preventing tumor recurrence can be achieved.

The invention belongs to the technical field of biomedical materials, and particularly relates to a multifunctional compound stent as well as a preparation method and application thereof. The multifunctional composite scaffold comprises a bone tissue scaffold and a functional layer, the functional layer is arranged on the surface of the bone tissue stent and comprises a photo-thermal layer and a medicine carrying layer; or, the functional layer is a mixed layer, and the mixed layer comprises a photo-thermal reagent and a chemotherapeutic drug. The preparation method of the bone tissue scaffold comprises the following steps: acquiring bone medical image data of a part to be implanted, converting the bone medical image data into three-dimensional model data of bones, and preparing the bone tissue scaffold through 3D printing processing according to the three-dimensional model data. The invention provides a multifunctional compound scaffold as well as a preparation method and application thereof, which can efficiently kill residual tumor cells and fill postoperative bone defect positions at the same time, and can effectively solve the technical problems of single function, low tumor treatment efficiency and difficulty in removing the residual tumor cells in the existing scaffold for treating bone cancer.

The present invention relates to methods using newly identified cancer related polynucleotides and the polypeptides encoded by these polynucleotides. The invention further relates to the use of such “cancer antigens” for diagnosing cancer and cancer metastases. The invention relates to the use of these cancer antigens employing expression vectors, host cells, antibodies directed to such cancer antigens, and recombinant methods and synthetic methods for producing the same. Also provided are diagnostic and prognostic methods for detecting, treating, or preventing cancer, for suppressing tumor progression and minimal residual tumor disease, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of the cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polynucleotides and polypeptides of the present invention.

The invention relates to the technical field of immunization, in particular to a polyinosinic: polycytidylic acid copolymer (Poly I: C). The polyinosinic: polycytidylic acid copolymer is a ligand of atype-3 Toll-like receptor in an animal body, can mediate a series of immune reactions of the body after TLR-3 is activated, and has a good promoting effect on specific immunity and non-specific immunity of the body. Compared with a control group, DC-CIK induced by the polyinosinic: polycytidylic acid copolymer has higher proliferation, high differentiation (especially CD3+CD4-CD8+, CTL) and hightumor killing activity. The autologous efficient DC-CIK induced by the polyinosinic: polycytidylic acid copolymer and other immune cells are applied to treatment of clinical tumor patients. The polyinosinic: polycytidylic acid copolymer aims to recover or improve the immune function of the tumor patients, and the immune system of the body is improved to kill and inhibit proliferation of tumor cells. The tumor cell load is reduced, tiny residual lesions are removed, or the proliferation mode of residual tumor / cancer cells is obviously inhibited, factors such as relapse and metastasis are eliminated, the cure possibility is increased, the survival time is prolonged, and the life quality is improved. Therefore, the purpose of treating tumors / cancers is achieved.

The present invention provides chimeric antigen receptor-modified T cells capable of self-expressing PD-1 antibody and targeting mesothelin and uses thereof. The T cells of the present invention self-express PD1 antibodies and target mesothelin, and preferably contain (1) a coding sequence of a chimeric antigen receptor that expresses and recognizes mesothelin and a coding sequence of a PD-1 antibody, and / or (2) the chimeric antigen receptor that expresses and recognizes mesothelin and the PD-1 antibody. The T cells of the present invention inhibit the immune checkpoint PD-1 / PD-L1 pathway during the adoptive cellular immunotherapy, and can activate the function of the residual tumor specific T cells in situ, increase the antitumor killing effect of endogenous cytotoxic T cells, and promotethe proliferation of CAR-T cells in vivo, thereby improving the curative effect of specifically killing tumors.

A sustained-release gel injection comprises angiogenesis inhibitor, amphiphilic block copolymer, solvent and release regulator, wherein the mixture of amphiphilic block copolymer and solvent has temperature sensitive gelatinization characteristic, and can automatically become non-flowing degradable water insoluble gel, which can locally and slowly release drug at tumor foci for several weeks to several months, after injection into body. The preparation can be injected into or around tumor for treating solid tumors at different stages and metastatic tumors with remarkably reduced systemic toxicity of drug. The angiogenesis inhibitor is selected from alemtuzumab,ibritumomab, bevacizumab, rituximab, gemtuzumab ozogamicin, panitumumab, trastuzumab, celebrex, refecoxib, tositumomab, endostatain, engiostatin, toxitumomab, and cetuximab. The preparation has effects of controlling residual tumor cell relapse after operation and tumor can not be excised via operation, controlling complications at late stage of tumor, and enhancing treatment effect of chemotherapy and radiotherapy (particularly radioactive particles).

The invention discloses near-infrared fluorescence dye for targeting tumor tissue. The structure of the near-infrared fluorescence dye for targeting tumor tissue is shown in formula I. Additionally, the invention further discloses a preparation method and an application of the near-infrared fluorescence dye. The near-infrared fluorescence dye has the characteristics of water solubility, near-infrared color rendering, tumor cell targeting and the like and is applicable to transmission in in-vivo environment; a near-infrared fluorescence area has color rendering, eliminates disturbance of other light sources and can serve as near-infrared dye; meanwhile, accumulation of the dye around the tumor tissue is improved according to a folic acid targeting principle, specific locus recognition capacity is provided, and the near-infrared fluorescence dye can serve as dye in a tumor resection operation and used for targeting near-infrared images of tumor cells. The property of the near-infrared fluorescence dye helps surgeons to look for and judge positions of tumor tissue in time in an operation process, the purpose of eradicating residual tumors is achieved, and the near-infrared fluorescence dye has a wide application prospect in the field of targeted color rendering of the tumor cells in an medical operation.

The invention provides a novel method for treating osteosarcoma, and application of photodynamic therapy and equipment and a photosensitizer to treating osteosarcoma, wherein the photosensitizer can be selectively gathered in osteosarcoma cells. Animal in vivo experiments show that PDT taking HMME as the photosensitizer can be used for effectively inhibiting growth of osteosarcoma, and moreover, a wide necrotic zone which is homogenously red-stained at the tumor site is observed by virtue of HE staining; the wide necrotic zone is black and is incrustated in the periphery with a lot of inflammatory cells infiltrated; residual tumor cells have changes in karyopyknosis, vacuolar degeneration and the like. According to the invention, HMME-PDT is verified for the first time that HMME-PDT is mainly used for inducing apoptosis of osteosarcoma cells and is closely related to a caspase dependent apoptosis pathway.

The invention relates to a photothermal agent for photothermal therapy of tumors. A compound formed by quercetin and iron ions or ferrous ions through coordinate bonds is wrapped in a micelle (QFM) formed by an amphiphilic polymer, and the photothermal agent has a better photothermal effect and can effectively kill tumor cells when being used for photothermal therapy of tumors. Quercetin released from the micelle can reduce expression of programmed death ligand 1 (PD-L1) of tumor cells and remarkably promote lymphocytes to infiltrate into the tumor to kill residual tumor cells, and part of QFM can also target lymph nodes after intratumor injection; the released quercetin can significantly reduce PD-L1 on the surface of the dendritic cell, so that the ability of presenting tumor cell antigen of the dendritic cell is enhanced. After treatment, the number of memory T cells in the spleen of the mouse is obviously increased, so that the organism forms long-term immune memory on tumor cells, and tumor recurrence is effectively prevented.